Malta - inglise - Medicines Authority

specifar s.a. 1, 28 octovriou street. ag. varvara 123 51 athens, greece - meclozine hydrochloride - tablet - meclozine hydrochloride 30 mg - antihistamines for systemic use

Malta - inglise - Medicines Authority

specifar s.a. 1, 28 octovriou street. ag. varvara 123 51 athens, greece - finasteride - film-coated tablet - finasteride 5 mg - urologicals

Malta - inglise - Medicines Authority

specifar s.a. 1, 28 octovriou street. ag. varvara 123 51 athens, greece - alfuzosin hydrochloride - prolonged-release tablet - alfuzosin hydrochloride 10 mg - urologicals

Malta - inglise - Medicines Authority

specifar s.a. 1, 28 octovriou street. ag. varvara 123 51 athens, greece - clopidogrel - film-coated tablet - clopidogrel 75 mg - antithrombotic agents

Malta - inglise - Medicines Authority

specifar s.a. 1, 28 octovriou street. ag. varvara 123 51 athens, greece - tamsulosin hydrochloride - prolonged-release capsule - tamsulosin hydrochloride 0.4 mg - urologicals

Armeenia - inglise - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

specifar sa - clopidogrel (clopidogrel besilate) - tablets film-coated - 75mg

Malaisia - inglise - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

actavis sdn. bhd. - glimepiride -

Euroopa Liit - inglise - EMA (European Medicines Agency)

actavis group ptc ehf    - pioglitazone hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:as monotherapy:in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

Euroopa Liit - inglise - EMA (European Medicines Agency)

actavis group ptc ehf - topotecan - uterine cervical neoplasms; small cell lung carcinoma - antineoplastic agents - topotecan monotherapy is indicated for the treatment of patients with relapsed small cell lung cancer [sclc] for whom re-treatment with the first-line regimen is not considered appropriate. topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage ivb disease. patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.,

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

valeant pharmaceuticals new zealand ltd - metoclopramide hydrochloride monohydrate 5 mg/ml;  ;   - solution for injection - 5 mg/ml - active: metoclopramide hydrochloride monohydrate 5 mg/ml     excipient: sodium chloride water for injection